Advanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
(Exact name of Company as specified in its charter)
| (State or other jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices)
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Item 1.01 Entry into a Material Definitive Agreement.
On April 13, 2026, Advanced Biomed Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Jie Wang (the “Lender”), pursuant to which the Lender lent to the Company a principal amount of Six Hundred Thousand United States Dollars (US$600,000) (the “Loan”).
The Loan bears interest at an annual rate of ten percent (10%) per annum, accruing from the date the Loan proceeds are disbursed to the Company (the “Disbursement Date”). The term of the Loan is six (6) months from the Disbursement Date (the “Maturity Date”). Upon the mutual written agreement of the parties, the term may be extended for six (6) additional months.
On or before the Maturity Date, the Company is required to repay the full principal amount of US$ 600,000, together with all accrued and unpaid interest. The Company may prepay the Loan, in whole or in part, at any time without penalty or premium, with any partial prepayment applied first to accrued interest and then to outstanding principal.
The Loan is unsecured. The Loan Agreement is governed by the laws of the State of New York, and any disputes arising thereunder shall be resolved in the courts of the State of New York.
The Company plans to use the proceeds from the Loan for operation.
The foregoing description of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statement and Exhibits.
| Exhibit No. | Description | |
| 10.1 | Loan Agreement, dated April 13, 2026, between Advanced Biomed Inc. and Jie Wang. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Advanced Biomed Inc. | ||
| Date: April 14, 2026 | By: | /s/ Yi Lu |
| Yi Lu | ||
| Chief Executive Officer | ||
2